Ge Long Hui A P P·2026-01-22 10:26Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a drug, which is indicated for the treatment of acute hypotensive states and can assist in the treatment of cardiac arrest and shock [1] Group 1 - The approved drug is a formulation of norepinephrine bitartrate injection [1] - The indications for the drug include restoring blood pressure in acute hypotensive states, assisting in cardiac arrest treatment, and maintaining blood pressure post-cardiac arrest [1] - The drug is also indicated as an auxiliary treatment for shock due to hypovolemia, aimed at temporarily maintaining cerebral and coronary perfusion until volume resuscitation takes effect [1]